Gvoke HypoPen

Primary Use

Gvoke HypoPen is prescribed for the emergency treatment of severe hypoglycemia in adults and pediatric patients aged 2 years and older who have diabetes. Severe hypoglycemia occurs when blood sugar levels drop so low that the person becomes unable to help themselves and requires assistance from another person.

When It Is Used

This medication is intended for use in emergency situations where a person with diabetes cannot safely consume sugar by mouth. These situations may include when the person is:

• Unconscious or unresponsive.
• Having a seizure.
• Too confused or physically impaired to swallow food or drink safely.

Gvoke HypoPen is a rescue medication and is not meant for the daily or routine management of blood sugar levels. It is designed to be kept on hand by patients, family members, or caregivers so it can be administered immediately when a severe low blood sugar event occurs.

Mechanism of Action

Gvoke HypoPen contains glucagon, a hormone that is naturally produced by the pancreas. Its primary role is to increase blood glucose levels when they become dangerously low.

When injected, the medication works through the following process:

• Glucose Release: It signals the liver to break down stored sugar, known as glycogen, into glucose.
• Bloodstream Entry: This glucose is then released directly into the bloodstream.
• Restoring Balance: As blood sugar levels rise, the symptoms of severe hypoglycemia begin to improve.

This process is essential during a diabetic emergency when a person is unable to consume sugar by mouth due to confusion, unconsciousness, or the inability to swallow.

Common Side Effects

The most frequent side effects reported with Gvoke HypoPen include:

• Nausea
• Vomiting
• Headache
• Injection site reactions, such as redness, swelling, or itching
• Abdominal pain

Serious Side Effects

While less common, some side effects can be serious and require immediate medical attention:

• Severe allergic reactions: Symptoms may include a widespread rash, hives, swelling of the face or throat, and difficulty breathing.
• High blood pressure and heart rate: Some individuals may experience a temporary increase in blood pressure or a rapid heartbeat.
• Low blood sugar (hypoglycemia): After the initial treatment raises blood sugar, levels may drop again once the medication wears off. To prevent this, it is important to consume carbohydrates and protein as soon as the person is able to swallow safely.

Contraindications

Gvoke HypoPen should not be used in individuals with the following medical conditions:

• Pheochromocytoma: Glucagon can cause a tumor in the adrenal gland to release catecholamines, which may lead to a sudden and dangerous increase in blood pressure.
• Insulinoma: In people with an insulin-producing tumor, glucagon may stimulate a rapid release of insulin, which can cause a secondary and severe drop in blood sugar.
• Glucagonoma: Similar to insulinoma, this condition increases the risk of secondary hypoglycemia following glucagon administration.
• Hypersensitivity: This medication is contraindicated in anyone with a known history of severe allergic reactions to glucagon or any of the inactive ingredients in the device.

Major Warnings and Precautions

Severe Allergic Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported. Symptoms may include a generalized rash, difficulty breathing, and low blood pressure. Emergency medical assistance is required if these symptoms occur.

Risk of Secondary Hypoglycemia

Glucagon administration can trigger the pancreas to release insulin, which may cause blood sugar levels to fall again after the initial treatment. To prevent this, the individual should consume fast-acting carbohydrates (such as fruit juice or glucose gel) and a long-acting protein as soon as they are conscious and able to swallow safely.

Limited Effectiveness in Certain Conditions

Glucagon works by signaling the liver to release stored glucose. It may not be effective in individuals who have low liver glycogen stores, such as those experiencing prolonged fasting, starvation, adrenal insufficiency, or chronic hypoglycemia. In these situations, intravenous glucose may be necessary to treat severe hypoglycemia.

Necrolytic Migratory Erythema (NME)

A skin condition called necrolytic migratory erythema has been reported with glucagon use. This rash may be painful or itchy and can appear anywhere on the body. If a persistent or worsening rash develops, a healthcare provider should be notified.

Blood Pressure Monitoring

In some cases, glucagon may cause a temporary increase in blood pressure and heart rate. Monitoring may be necessary for individuals with underlying cardiovascular conditions.

Pregnancy

Glucagon is a hormone that occurs naturally in the human body. Decades of clinical use suggest that using glucagon during pregnancy does not increase the risk of major birth defects, miscarriage, or other adverse health outcomes for the mother or the baby. Research indicates that the medication does not cross the placenta in significant amounts.

Breastfeeding

It is currently unknown if glucagon passes into human breast milk or what effects it may have on a nursing infant. However, because glucagon is a protein, it is expected to be broken down in the infant's digestive system, which makes it unlikely to cause harm. There is no evidence that the medication affects milk production.

Patients are encouraged to discuss the use of this medication with their healthcare provider if they are pregnant, breastfeeding, or planning to become pregnant.

Available Forms

Gvoke HypoPen is provided as a pre-filled, single-use autoinjector. It contains a stable liquid formulation of glucagon, which eliminates the need for manual mixing or reconstitution before use.

The device is designed for subcutaneous injection and features an automated delivery system. Once activated, the needle retracts into the device after the dose is delivered.

This medication is available in different sizes intended for use based on the patient's age or weight, though each utilizes the same autoinjector technology.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Gvoke in September 2019. It is indicated for the treatment of severe hypoglycemia (extremely low blood sugar) in adult and pediatric patients aged 2 years and older who have diabetes.

Regulatory Status

Gvoke is classified as a prescription-only medication. It was the first liquid-stable glucagon formulation approved for use in a pre-filled autoinjector. Unlike traditional glucagon emergency kits that require the user to manually mix a powder and liquid before administration, this regulatory approval covered a ready-to-use format designed for rapid delivery during an emergency.

Safety Oversight

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for Gvoke HypoPen. The medication has not been subject to major safety-related recalls or public health communications since its initial approval. It is intended for use only in emergency situations where the patient is unable to consume oral carbohydrates due to severe low blood sugar.

Treating Severe Hypoglycemia

Severe hypoglycemia is a medical emergency that occurs when blood sugar levels drop so low that a person requires assistance from others. Symptoms may include extreme confusion, seizures, or loss of consciousness. Gvoke HypoPen is used to quickly raise blood sugar levels by triggering the liver to release stored glucose into the bloodstream.

When to Use Gvoke HypoPen

This medication should be used if a person with diabetes is experiencing very low blood sugar and:

• Is unable to swallow or eat safely.
• Is unconscious or having a seizure.
• Does not respond to oral sugar treatments.

Emergency Steps

Because severe hypoglycemia is life-threatening, certain steps should be taken during and after administration:

• Administer the injection: Use the autoinjector in the outer thigh, upper outer arm, or buttock.
• Call for help: Contact emergency medical services immediately after giving the dose.
• Positioning: Turn the person onto their side to prevent choking, as vomiting is a common side effect of glucagon.
• Follow-up: Once the person is conscious and able to swallow, they should consume a fast-acting source of sugar, such as fruit juice or glucose tablets, followed by a long-acting carbohydrate like a snack with protein.